NewGenIvf Group Limited (NASDAQ:NIVF – Get Free Report) was the target of a large growth in short interest during the month of June. As of June 30th, there was short interest totaling 654,534 shares, a growth of 631.2% from the June 15th total of 89,521 shares. Based on an average trading volume of 18,460,916 shares, the days-to-cover ratio is presently 0.0 days. Approximately 28.6% of the company’s shares are sold short.
Analyst Ratings Changes
A number of equities analysts recently weighed in on NIVF shares. Weiss Ratings reaffirmed a “sell (d)” rating on shares of NewGenIvf Group in a research note on Monday, April 27th. Wall Street Zen upgraded NewGenIvf Group to a “hold” rating in a report on Saturday, July 4th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company currently has a consensus rating of “Sell”.
Check Out Our Latest Analysis on NewGenIvf Group
NewGenIvf Group Stock Performance
NewGenIvf Group (NASDAQ:NIVF – Get Free Report) last posted its quarterly earnings data on Tuesday, March 31st. The company reported ($861.72) earnings per share (EPS) for the quarter. The firm had revenue of $1.42 million for the quarter. As a group, analysts anticipate that NewGenIvf Group will post 14.22 EPS for the current year.
Insiders Place Their Bets
In other news, major shareholder Financial Lp Hrt acquired 45,847 shares of the firm’s stock in a transaction that occurred on Friday, May 22nd. The stock was purchased at an average price of $2.97 per share, for a total transaction of $136,165.59. Following the completion of the acquisition, the insider owned 37,295 shares in the company, valued at $110,766.15. This trade represents a -536.10% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. 31.80% of the stock is owned by insiders.
NewGenIvf Group Company Profile
NewGenIVF Group Inc, trading on NASDAQ under the symbol NIVF, is an integrated provider of reproductive medicine services in the People’s Republic of China. The company operates a network of fertility clinics across major Chinese cities, delivering comprehensive infertility diagnosis and treatment to patients and couples. Its facilities are equipped with modern laboratories and surgical suites designed for assisted reproductive procedures.
NewGenIVF’s service offerings encompass a wide range of assisted reproductive technologies (ART), including in vitro fertilization (IVF), intracytoplasmic sperm injection (ICSI), preimplantation genetic testing (PGT), and fertility preservation through ovarian tissue and gamete cryopreservation.
Further Reading
- Five stocks we like better than NewGenIvf Group
- Starbucks Builds Sovereign AI to Cut $400 Million in Software Costs
- Power Struggle: Wolfspeed Sues Navitas Over AI Chips
- Why WD-40 Is Proving Great Businesses Never Go Out of Style
- Pushing the Edge: Super Micro Computer Reboots the AI Landscape
Receive News & Ratings for NewGenIvf Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewGenIvf Group and related companies with MarketBeat.com's FREE daily email newsletter.
